COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 3 of 3 for:    sevuparin

Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01442168
Recruitment Status : Terminated
First Posted : September 28, 2011
Last Update Posted : August 19, 2014
University of Oxford
Information provided by (Responsible Party):
Modus Therapeutics AB

Brief Summary:

The purpose of this study is to determine the tolerability and pharmacokinetics of Sevuparin/DF02 when administered as an i.v. infusion in combination with Malanil® (atovaquone/proguanil) as anti-malarial treatment in subjects affected with uncomplicated malaria. The study will also assess the potential of Sevupatin/DF02 to reduce infected erythrocyte sequestration and rosette formation.

The study consists of a dose escalation part (part 1) followed by an open labelled, randomized comparison of treatment with Sevuparin/DF02 and Malanil® versus Malanil® alone (part 2).

Condition or disease Intervention/treatment Phase
Malaria, Falciparum Drug: Sevuparin sodium + atovaquone/proquanil Drug: atovaquone/proquanil Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 53 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria
Study Start Date : September 2011
Actual Primary Completion Date : September 2013
Actual Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria
Drug Information available for: Atovaquone

Arm Intervention/treatment
Experimental: Sevuparin/DF02
Sevuparin/DF02 plus anti-malarial regimen (Malanil®)
Drug: Sevuparin sodium + atovaquone/proquanil
Sevuparin 4 times per day and malanil according to label

Active Comparator: Control
Anti-malarial regimen (Malanil®) alone
Drug: atovaquone/proquanil
malanil according to label

Primary Outcome Measures :
  1. Dose limiting toxicities according to specified criteria [ Time Frame: During treatment and 14 days post treatment follow-up. ]
  2. Area under the curve of late stage peripheral blood parasitemia over time (Part 2). [ Time Frame: 72 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Presence of acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of a single species (P. falciparum)
  • Counts of asexual forms of P. falciparum: 10 000- 100 000/ul with or without gametocytaemia
  • Presence of fever defined as > 38°C tympanic temperature or a history of fever within the last 24 hours

Exclusion Criteria:

  • Mixed infection with other Plasmodium species
  • Any criteria of severe or complicated malaria as defined by the WHO, 2010
  • Use of high doses aspirin (more than 100 mg/day) or dual anti-platelet therapy or use of heparin,Low Molecular Weight Heparin (LMWH) or warfarin
  • Presence of significant anemia as defined by Hb <8 g/dL or Hct < 25%
  • A platelet count < 50,000/μL
  • Presence of febrile conditions caused by diseases other than malaria

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01442168

Layout table for location information
Mae Ramat Hospital
Mae Ramat, Tak province, Thailand
Maesot General hospital
Mae Sot, Tak Province, Thailand
Hospital for Tropical Diseases
Bangkok, Thailand
Sponsors and Collaborators
Modus Therapeutics AB
University of Oxford
Layout table for investigator information
Study Director: Anna Leitgeb, PhD Modus Therapeutics AB
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Modus Therapeutics AB Identifier: NCT01442168    
Other Study ID Numbers: Sevuparin/DF02_TSM02
First Posted: September 28, 2011    Key Record Dates
Last Update Posted: August 19, 2014
Last Verified: August 2014
Keywords provided by Modus Therapeutics AB:
Uncomplicated Falciparum Malaria
Plasmodium falciparum
Antimalarial treatment
Adjuvant therapy
Peripheral blood parasitemia
Rosette formation
Maximum tolerated dose
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action